Slide 1: Half-Year Report January-June 2026
Half-Year Report January-June 2026 17 July 2026
Slide 2: Disclaimer
Disclaimer The following applies to this presentation, the oral presentation of the information in this presentation by Oriola Corporation (the “Company” or “Oriola”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the “In
Slide 3: Agenda
Agenda 1 Q2 2026 highlights 2 Operating environment 3 Segments 4 Financial review Q&A Q2 2026 17 JULY 2026 3
Slide 4: Continued net sales growth in Product segment, Group profitability at last year’s level
Continued net sales growth in Product segment, Group profitability at last year’s level • Positive sales development in the wholesale business in Finland continued. • Volumes in speciality flows remained at a high level, demand for Oriola’s pharmaceutical Q2 26 distribution services somewhat weaker
Slide 5: Operating environment
Operating environment • In the second quarter, the value of the pharmaceutical distribution market grew in Sweden (9.9%), while growth in Finland remained low (0.2%). • Geopolitical developments continued to contribute to an uncertain operating environment, with high fuel prices and inflationary pre
Slide 6: Q2: Services segment
Q2: Services segment • Net sales declined 2% to EUR 37.1 • In advisory services, restructuring (37.9) million. measures have been implemented to • Net sales decline due to the weak reduce personnel costs. quarter in pharmaceutical distribution in • Adjusted EBITDA decreased to EUR Sweden and advisor
Slide 7: Q2: Products segment
Q2: Products segment • Net sales grew 11% to EUR 16.9 (15.2) • Adjusted EBITDA was EUR 1.0 (1.1). million. • Adjusted EBITDA margin was 5.9% • Growth supported by both the wholesale (7.3%). and dose dispensing businesses in • The decline in adjusted EBITDA was due Finland. to higher operating expens
Slide 8: Financial review
Financial review Q2 2026 17 JULY 2026 8
Slide 9: Invoicing and net sales
Invoicing and net sales Invoicing EUR million Net sales EUR million +5.3% 1,129 50.9 +1.7% 51.8 1,073 4-6 2026 • Invoicing growth was driven by both Services and Products segments. • Net sales growth was driven by the Products segment. Q2 25 Q2 26 Q2 25 Q2 26 +6.6% 2,210 101.9 -0.3% 101.6 1-6 2026 2
Slide 10: EBITDA
EBITDA Adjusted EBITDA EUR million 4-6 2025 • Adjusted EBITDA margin 15.6% (15.8%). • Adjusting items totalled EUR -4.2 (-6.5) million and included EUR 15.6 15.7 -3.7 million ERP investment related implementation cost in Group administration. EBITDA was EUR 3.9 (1.6) million. 6.6 8.1 8.1 8.1 1-6 202
Slide 11: Services segment
Services segment Invoicing EUR million Net sales EUR million Adjusted EBITDA EUR million +6.8% -2.0% +0.7% 2,182 37.9 37.1 73.2 73.7 +5.2% 2,044 9.3 -2.6% 9.0 -3.8% 17.7 17.1 1,060 1,114 Q2 25 Q2 26 YTD 25 YTD 26 Q2 25 Q2 26 YTD 25 YTD 26 Q2 25 Q2 26 YTD 25 YTD 26 4-6 2026 4-6 2026 • Invoicing grew
Slide 12: Products segment
Products segment Net sales EUR million Adjusted EBITDA EUR million 35.1 -8.2% +11.2% 32.3 16.9 Excl. Swedish dose 15.2 dispensing business, net sales grew by 10.6% Excl. Swedish dose +45% dispensing business, 3.1 adjusted EBITDA -10% 2.2 was EUR 3.1 (2.0) million 1.1 1.0 and adjusted EBITDA margin 9
Slide 13: Improved net profit for H1 compared to last year
Improved net profit for H1 compared to last year Net profit EUR million 9.1 2026 1-6 2026 -6.5 1-6 • EBITDA above last year due to lower adjusting items. 2.6 • Adjusting items totalled EUR -6.6 (-8.1) million and -3.4 included EUR -6.0 million ERP investment related -2.5 implementation costs in Grou
Slide 14: Free cash flow
Free cash flow Free cash flow EUR million 1-6 1-6 Abs. 1-6 2026 EUR million 2026 2025 change • EBITDA above last year due to lower adjusting items. EBITDA 9.1 7.5 1.6 • Increase in trade receivables has negatively impacted working capital, primarily due to a reduced number of Adjustments 0.4 2.9 -2.
Slide 15: Net debt on a low level
Net debt on a low level Net interest-bearing debt EUR million Net interest-bearing debt items Jun Jun Abs. EUR million 2026 2025 change Bank loans (syndicated bank & term) 30.0 30.0 0.0 -7 -13 Commercial papers 26.8 19.9 6.9 Advance payment from pharmacies 10.3 10.9 -0.6 -37 -37 -35 Lease liabilitie
Slide 16: Solid financial position
Solid financial position Gearing and equity ratio % Gearing Equity ratio 16 15 16 13 12 12 June 2026 • The adjusting items (mainly ERP) and the negative result from Kronans Apotek had a negative impact on the net result and the equity ratio compared to June last year. -31 • Negative cash flow impact
Slide 17: Kronans Apotek (Swedish Pharmacy Holding)
Kronans Apotek (Swedish Pharmacy Holding) 2026 2025 Change 2026 2025 Change 2025 Key figures EUR million 4-6 4-6 % 1-6 1-6 % 1-12 Net sales 332.6 313.5 6.1 655.9 608.7 7.7 1223.1 EBITA 2.7 -2.6 -204.4 0.9 -1.7 151.2 -4.4 EBIT 0.4 -1.4 128.0 -3.8 -6.2 39.2 -45.0 Adjusted EBIT 0.8 -3.3 122.8 -2.2 -3.1
Slide 18: Outlook
Outlook In 2026, the pharmaceutical distribution market is expected to continue to grow. Value growth is expected to be driven by high-value pharmaceuticals and products requiring advanced logistics. The uncertainty in the geopolitical environment remains, and the availability issues of certain phar
Slide 19: Q2 26 Key takeaways
Q2 26 Key takeaways Continued net sales growth in Supply chain remained stable In H2, net sales growth and Product segment. Volumes in despite operating environment efficiency improvement speciality flows remained at a uncertainty. expected to continue. Cost high level. discipline a key priority.
Slide 20: Our next events / Thank you for joining us today!
Our next events 29 October 2026 Q3 2026 report Thank you for joining us today!
Slide 21: Health for life
Health for life